ReviewInternational journal of inflammation2013
Thromboangiitis Obliterans (Buerger's Disease)-Current Practices.
Review in International journal of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 98 citations in OpenAlex.
- Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience.Stem cell research & therapy · 2020Trial
- Purified CD34EBioMedicine · 2018Trial
- Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.Stem cells translational medicine · 2017Trial
- Efficacy of the Tibial Transverse Bone Transport Technique in the Management of Thromboangiitis Obliterans: A Systematic Review.Journal of clinical medicine · 2026Review
- Diabetic Peripheral Arterial Disease Versus Thromboangiitis Obliterans: A Multidimensional Comparison of Clinical Phenotype, Biomarkers, and Outcomes.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical outcomes of critical limb ischemia in Buerger disease: A contemporary analysis from an academic referral center in Jordan.PloS one · 2026Article
- Indocyanine Green Angiography in the Evaluation of Surgical Amputation Level in Patients with Arterial Ulcers Due to Thromboangiitis Obliterans.Medicina (Kaunas, Lithuania) · 2025Article
- The Safety and Effectiveness of Interval Stellate Ganglion Neurolysis in a Patient with Bilateral Digital Ischemia of Hands Due to Buerger's Disease: A Case Report.Journal of orthopaedic case reports · 2024Article
- Levistolide a Attenuates Acute Kidney Injury in Mice by Inhibiting the TLR-4/NF-κB Pathway.Drug design, development and therapy · 2024Article
- Comparative Analysis of Transcriptome Profiles in Patients with Thromboangiitis Obliterans.Genes · 2023Article
- Management of Buerger's disease during pregnancy.BMJ case reports · 2023Article
- Successful lumbal sympathetic block as an alternative therapy for improving Buerger's disease: A rare case report and literature review.International journal of surgery case reports · 2023Article
- A 61-year-old with heavy tobacco use.Journal of the American College of Emergency Physicians open · 2023Article
- Decreasing tobacco use promotes ulcer healing in a patient with Buerger's disease.Clinical case reports · 2023Article
- Psychiatric sequelae of thromboangiitis obliterans: a case report and review of the literature.Journal of medical case reports · 2023Review
- Article
- Autologous Stem Cells Transplantation for No-Option Angiitis-Induced Critical Limb Ischemia: Recurrence and New Lesion.Stem cells translational medicine · 2022Article
- A Rare Case of Thromboangiitis Obliterans of Bilateral Upper Extremities in an Adult Male.Cureus · 2022Article
- An improved bone transport surgical method for treating chronic ischemic ulcers (thromboangiitis obliterans).Frontiers in surgery · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental inflammatory disease that most commonly affects the small and medium-sized arteries and veins in the upper and lower extremities. Cigarette smoking has been implicated as the main etiology of the disease. In eastern parts of the world TAO forms 40-60% of peripheral vascular diseases. Clinical features and angiographic finding are the basis of early diagnosis of TAO. Abstinence from smoking is the only definitive treatment to prevent disease progression. Medical management in form of aspirin, pentoxyfylline, cilostazol, and verapamil increase pain-free walking distance in intermittent claudication, but long term usage fails to prevent disease progression in patients who continue to smoke. Surgical treatment in form of revascularization, lumbar sympathectomy, omentopexy, and Ilizarov techniques help reduce pain and promote healing of trophic changes. Newer treatment modalities like spinal cord stimulation, prostacyclin, bosentan, VEGF, and stem cell therapy have shown promising results. Latest treatment options include peripheral mononuclear stem cell, and adipose tissue derived mononuclear stem cells have been shown to be effective in preventing disease progression, decrease major amputation rates, and improving quality of life.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.